Evidence map›Paper›PMID 40304585›Full record

SynthesisHepatology communications2025

Treatment of alcohol use disorder in alcohol-associated liver disease: A meta-analysis.

Ashwani K Singal, Wanyu Zhang, Akshay Shetty, Arpan Patel, Shaikhoon Mohammed, Prabha Bhandari, Mohamed Abdallah, Vatsalya Vatsalya, Lorenzo Leggio, Maiying Kong

Abstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Hepatology communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Addressing Alcohol Use Disorder in Alcohol-Associated Liver Disease.Clinical and translational gastroenterology · 2026
    Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ashwani K SingalDivision of Gastroenterology Hepatology Nutrition, University of Louisville School of Medicine, Louisville, Kentucky, USA.ORCID 0000-0003-1207-3998
Wanyu ZhangDivision of Gastroenterology Hepatology Nutrition, University of Louisville School of Medicine, Louisville, Kentucky, USA.
Akshay ShettyDepartment of Medicine and Division of Gastroenterology and Hepatology, University of California Los Angeles, Los Angeles, California, USA.
Arpan PatelDepartment of Medicine and Division of Gastroenterology and Hepatology, University of California Los Angeles, Los Angeles, California, USA.
Shaikhoon MohammedDepartment of Hospital Medicine, Emory University, Atlanta, Georgia, USA.
Prabha BhandariDivision of Infectious Disease, University of Louisville School of Medicine, Louisville, Kentucky, USA.
Mohamed AbdallahDivision of Gastroenterology, Cleveland Clinic, Ohio, USA.
Vatsalya VatsalyaDepartment of Medicine, University of Louisville School of Medicine, Louisville, Kentucky, USA.
Lorenzo LeggioClinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse Intramural Research Program and National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research, National Institutes of Health, Bethesda, Maryland, USA.
Maiying KongDepartment of Bioinformatics and Biostatistics, School of Public Health and Information Sciences, University of Louisville, Kentucky, USA.

Funding

WKU Lead Faculty AwardP20GM103436 · NIGMS · UNIVERSITY OF LOUISVILLE · PI ERIC C ROUCHKA · 2012 to 2026
$60.1M
Research Design, Compliance, and Data Management (RDCD)P20GM155899 · NIGMS · UNIVERSITY OF LOUISVILLE · PI Jon Klein · 2024 to 2026
$9.3M
Integrated therapies for alcohol use and ALD (ITAALD) Network -UofL Clinical CenterU01AA026980 · NIAAA · UNIVERSITY OF LOUISVILLE · PI CRAIG J. MCCLAIN, Ashwani K Singal · 2018 to 2026
$2.9M
NIAAA NIH HHS U01 AA026980NIGMS NIH HHS P20 GM103436NIGMS NIH HHS P20 GM155899
6 · The paper itself

Abstract

backgroundTo examine alcohol use disorder (AUD) treatment in patients with alcohol-associated liver disease (ALD) on alcohol relapse and liver-related outcomes. METHODS AND

resultsTwenty-five eligible studies on 93,899 (33,834 AUD intervention) patients with ALD were analyzed. Data presented as HR, with a 95% CI. Of 14 studies in patients with ALD outside the liver transplantation (LT) setting, pooled data from 7 randomized controlled trials (RCTs) showed that AUD treatment reduces alcohol relapse by 73% (HR: 0.27, 95% CI: 0.15-0.46) with any treatment and by 77% (HR: 0.23, 95% CI:0.14-0.39) with medications in 5 RCTs on 322 (186 intervention) patients. AUD treatment from observational studies was associated with reduced readmission (5 studies) by 48% and decompensation (2 studies) by 52%, but not patient mortality (3 studies). Data showed moderate to high heterogeneity, without publication bias. Analysis of 8 observational studies on LT recipients showed that AUD treatment reduced alcohol relapse in the post-LT period by 59%, with 58% and 60% reduction using integrated and nonintegrated models, respectively. AUD treatment among LT recipients was associated with a reduction in patient mortality by 56% in 3 observational studies, but not in 2 RCTs (HR: 0.82, 95% CI: 0.38-1.79). Pooled data were homogeneous in the analysis of alcohol relapse but showed moderate heterogeneity in analyzing patient mortality.

conclusionsAvailable data on AUD treatment in patients with ALD improves abstinence and liver-related outcomes both outside and within LT settings. RCTs are needed to examine (a) medications in patients with ALD to examine the benefit of alcohol relapse and patient outcomes and (b) the benefit of integrated multidisciplinary treatment to manage the dual pathology (AUD and liver disease).

Indexed as

AlcoholismLiver Diseases, AlcoholicHumansLiver TransplantationObservational Studies as TopicRandomized Controlled Trials as TopicRecurrenceSecondary PreventionTreatment OutcomeALDAUDcirrhosisMAUDrelapsetransplant

Identifiers

PMID40304585
PMCPMC12045530

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.